A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma

This study included phase Ib (safety introduction period) and phase II (randomizedcontrolled extension period).Phase Ib and Phase II each contain two independent cohorts, Cohort 1 and Cohort 2.After comprehensive evaluation by the sponsor and investigator, the safety andtolerability of combination therapy in Phase Ib Cohort 1 and Cohort 2 were good, andpreliminary efficacy was observed,Participants will be enrolled to conduct the twocohorts of phase II study.The Phase II study design will be adjusted based on resultsfrom the Phase Ib study.The population enrolled in Cohort 1 of Phase II will bedetermined by the results of Cohort 1A and Cohort 1B of Phase Ib.In Cohort 2 of Phase II,eligible participants were randomly assigned to the B1 group and B2 group in a 2: 1ratio.